Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
An increase in high-fat, high-fructose foods in people's diets has contributed to a dramatic increase in type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback